RESEARCH & DEVELOPMENT

ZERO DAY TARGETS

We have leveraged the unique ability of our SuperHuman2.0 antibody discovery technology to generate thousands of best-in-class molecules against 26 critical immune oncology and neurodegeneration targets, enabling our partners to save years of research time.  By combining our AI-based Tumbler technology, we bioengineer an internal portfolio of antibodies to address uniquely challenging therapeutic opportunities.